Published by
ACN Newswire
ACN Newswire
Offer Price Between HK$6.87and HK$7.38 per H ShareTo Raise Proceeds Up to HK$936.3 MillionEstablished an integrated end-to-end platform across drug discovery, clinical development and CMC and GMP-compliant manufacturingProduct pipeline with clinical efficacy and commercialization synergiesHONG KONG, Feb 10, 2022 – (ACN Newswire) – The biopharmaceutical company focusing on oncology therapeutics – Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, HKG: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (Hong Kong Stock Exc…